Non-alcoholic fatty liver disease: A patient guideline

S.M. Francque; G. Marchesini; A. Kautz; M. Walmsley; R. Dorner; J.V. Lazarus; S. Zelber-Sagi; K. Hallsworth; L. Busetto; G. Fruhbeck; D. Dicker; E. Woodward; M. Korenjak; J. Willemse; G.H. Koek; S. Vinker; M. Ungan; J.M. Mendive; C. Lionis

doi:10.1016/j.jhepr.2021.100322

Non-alcoholic fatty liver disease: A patient guideline

S.M. Francque^*, G. Marchesini, A. Kautz, M. Walmsley, R. Dorner, J.V. Lazarus, S. Zelber-Sagi, K. Hallsworth, L. Busetto, G. Fruhbeck, D. Dicker, E. Woodward, M. Korenjak, J. Willemse, G.H. Koek, S. Vinker, M. Ungan, J.M. Mendive, C. Lionis

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions. (C) 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).

Original language	English
Article number	100322
Number of pages	39
Journal	JHEP Reports
Volume	3
Issue number	5
DOIs	https://doi.org/10.1016/j.jhepr.2021.100322
Publication status	Published - 1 Oct 2021

Keywords

LIFE-STYLE MODIFICATION
SERUM ALANINE AMINOTRANSFERASE
PLACEBO-CONTROLLED TRIAL
Y GASTRIC BYPASS
QUALITY-OF-LIFE
BARIATRIC SURGERY
PHYSICAL-ACTIVITY
HEPATOCELLULAR-CARCINOMA
HEPATIC STEATOSIS
UNITED-STATES

Access to Document

10.1016/j.jhepr.2021.100322Licence: CC BY-NC-ND

Cite this

Francque, S. M., Marchesini, G., Kautz, A., Walmsley, M., Dorner, R., Lazarus, J. V., Zelber-Sagi, S., Hallsworth, K., Busetto, L., Fruhbeck, G., Dicker, D., Woodward, E., Korenjak, M., Willemse, J., Koek, G. H., Vinker, S., Ungan, M., Mendive, J. M., & Lionis, C. (2021). Non-alcoholic fatty liver disease: A patient guideline. JHEP Reports, 3(5), Article 100322. https://doi.org/10.1016/j.jhepr.2021.100322

@article{2bc97b3c991543839b990f56eb881f40,

title = "Non-alcoholic fatty liver disease: A patient guideline",

abstract = "This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions. (C) 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).",

keywords = "LIFE-STYLE MODIFICATION, SERUM ALANINE AMINOTRANSFERASE, PLACEBO-CONTROLLED TRIAL, Y GASTRIC BYPASS, QUALITY-OF-LIFE, BARIATRIC SURGERY, PHYSICAL-ACTIVITY, HEPATOCELLULAR-CARCINOMA, HEPATIC STEATOSIS, UNITED-STATES",

author = "S.M. Francque and G. Marchesini and A. Kautz and M. Walmsley and R. Dorner and J.V. Lazarus and S. Zelber-Sagi and K. Hallsworth and L. Busetto and G. Fruhbeck and D. Dicker and E. Woodward and M. Korenjak and J. Willemse and G.H. Koek and S. Vinker and M. Ungan and J.M. Mendive and C. Lionis",

note = "Funding Information: The authors would like to thank the patients from ECPO (European Coalition for People Living with Obesity), the patients from Deutsche Leberhilfe e.V. (German Liver Help Association), Ingo van Thiel (scientific editor of Deutsche Leberhilfe e.V), Ivan Gardini and Marco Bartoli (EpaC, Italian Liver Patients Association) and the Israelien patients who reviewed the document and provided their precious comments, as well as the Global Liver Institute. Funding Information: SMF has a senior clinical research mandate from the Fund for Scientific Research (FWO) Flanders (1802154 N) and has acted as advisor and/or lecturer for Roche, Gilead, Abbvie, Bayer, BMS, MSD, Janssen, Actelion, Astellas, Genfit, Inventiva, Intercept, Genentech, Galmed, Promethera, Coherus, NGM Bio and Julius Clinical. GM served as Advisory Board member for Sanofi, Novartis, Astra-Zeneca, Intercept and Pfizer, and participated in clinical trials by Sanofi, Eli Lilly, Gilead, GENFIT and Intercept. AK has received project grants from Novartis and Intercept. MW has nothing to disclose in relation to this publication. RD has received project grants from Novartis and Intercept. JVL received research grants from Gilead Sciences and MSD, and speaker fees from Genfit, Gilead Sciences, MSD, Intercept Pharmaceuticals and Janssen, outside of this work. SZS has nothing to disclose in relation to this publication. KH has nothing to disclose in relation to this publication. LB serves as an Advisory Board member for Novo Nordisk. GF has nothing to disclose in relation to this publication. DD served as Advisory Board member and lecture for Novo Nordisk, Sanofi, BI, Astra-Zeneca, and participated in clinical trials by, Novo Nordisk, Eli Lilly, Sanofi and BI. EW has nothing to disclose in relation to this publication. MK has nothing to disclose in relation to this publication. JW has nothing to disclose in relation to this publication. GK has nothing to disclose in relation to this publication. SV has nothing to disclose in relation to this publication. MU has nothing to disclose in relation to this publication. JM has nothing to disclose in relation to this publication. CL has nothing to disclose in relation to this publication. Publisher Copyright: {\textcopyright} 2021 The Authors",

year = "2021",

month = oct,

day = "1",

doi = "10.1016/j.jhepr.2021.100322",

language = "English",

volume = "3",

journal = "JHEP Reports",

publisher = "Elsevier BV",

number = "5",

}

Francque, SM, Marchesini, G, Kautz, A, Walmsley, M, Dorner, R, Lazarus, JV, Zelber-Sagi, S, Hallsworth, K, Busetto, L, Fruhbeck, G, Dicker, D, Woodward, E, Korenjak, M, Willemse, J, Koek, GH, Vinker, S, Ungan, M, Mendive, JM & Lionis, C 2021, 'Non-alcoholic fatty liver disease: A patient guideline', JHEP Reports, vol. 3, no. 5, 100322. https://doi.org/10.1016/j.jhepr.2021.100322

TY - JOUR

T1 - Non-alcoholic fatty liver disease: A patient guideline

AU - Francque, S.M.

AU - Marchesini, G.

AU - Kautz, A.

AU - Walmsley, M.

AU - Dorner, R.

AU - Lazarus, J.V.

AU - Zelber-Sagi, S.

AU - Hallsworth, K.

AU - Busetto, L.

AU - Fruhbeck, G.

AU - Dicker, D.

AU - Woodward, E.

AU - Korenjak, M.

AU - Willemse, J.

AU - Koek, G.H.

AU - Vinker, S.

AU - Ungan, M.

AU - Mendive, J.M.

AU - Lionis, C.

N1 - Funding Information: The authors would like to thank the patients from ECPO (European Coalition for People Living with Obesity), the patients from Deutsche Leberhilfe e.V. (German Liver Help Association), Ingo van Thiel (scientific editor of Deutsche Leberhilfe e.V), Ivan Gardini and Marco Bartoli (EpaC, Italian Liver Patients Association) and the Israelien patients who reviewed the document and provided their precious comments, as well as the Global Liver Institute. Funding Information: SMF has a senior clinical research mandate from the Fund for Scientific Research (FWO) Flanders (1802154 N) and has acted as advisor and/or lecturer for Roche, Gilead, Abbvie, Bayer, BMS, MSD, Janssen, Actelion, Astellas, Genfit, Inventiva, Intercept, Genentech, Galmed, Promethera, Coherus, NGM Bio and Julius Clinical. GM served as Advisory Board member for Sanofi, Novartis, Astra-Zeneca, Intercept and Pfizer, and participated in clinical trials by Sanofi, Eli Lilly, Gilead, GENFIT and Intercept. AK has received project grants from Novartis and Intercept. MW has nothing to disclose in relation to this publication. RD has received project grants from Novartis and Intercept. JVL received research grants from Gilead Sciences and MSD, and speaker fees from Genfit, Gilead Sciences, MSD, Intercept Pharmaceuticals and Janssen, outside of this work. SZS has nothing to disclose in relation to this publication. KH has nothing to disclose in relation to this publication. LB serves as an Advisory Board member for Novo Nordisk. GF has nothing to disclose in relation to this publication. DD served as Advisory Board member and lecture for Novo Nordisk, Sanofi, BI, Astra-Zeneca, and participated in clinical trials by, Novo Nordisk, Eli Lilly, Sanofi and BI. EW has nothing to disclose in relation to this publication. MK has nothing to disclose in relation to this publication. JW has nothing to disclose in relation to this publication. GK has nothing to disclose in relation to this publication. SV has nothing to disclose in relation to this publication. MU has nothing to disclose in relation to this publication. JM has nothing to disclose in relation to this publication. CL has nothing to disclose in relation to this publication. Publisher Copyright: © 2021 The Authors

PY - 2021/10/1

Y1 - 2021/10/1

N2 - This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions. (C) 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).

AB - This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions. (C) 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).

KW - LIFE-STYLE MODIFICATION

KW - SERUM ALANINE AMINOTRANSFERASE

KW - PLACEBO-CONTROLLED TRIAL

KW - Y GASTRIC BYPASS

KW - QUALITY-OF-LIFE

KW - BARIATRIC SURGERY

KW - PHYSICAL-ACTIVITY

KW - HEPATOCELLULAR-CARCINOMA

KW - HEPATIC STEATOSIS

KW - UNITED-STATES

U2 - 10.1016/j.jhepr.2021.100322

DO - 10.1016/j.jhepr.2021.100322

M3 - Article

C2 - 34693236

VL - 3

JO - JHEP Reports

JF - JHEP Reports

IS - 5

M1 - 100322

ER -

Non-alcoholic fatty liver disease: A patient guideline

Abstract

Keywords

Access to Document

Fingerprint

Cite this